Login to Your Account

Other news to note

Friday, January 8, 2016

Adaptimmune Therapeutics plc, of Oxford, U.K., said it is expanding its T-cell therapy development activities to target certain autoimmune diseases and named P. Julian Dyson to head that effort. Adaptimmune's goal is to restore the function of the immune system and inhibit the autoimmune response by delivering affinity enhanced regulatory T cells, or Tregs, to the site of the disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription